Compare SLNG & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLNG | VANI |
|---|---|---|
| Founded | 2013 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.0M | 81.2M |
| IPO Year | N/A | 2014 |
| Metric | SLNG | VANI |
|---|---|---|
| Price | $4.55 | $1.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $10.00 | $4.00 |
| AVG Volume (30 Days) | 5.3K | ★ 172.2K |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $72,270,000.00 | N/A |
| Revenue This Year | $7.02 | N/A |
| Revenue Next Year | $7.68 | N/A |
| P/E Ratio | $89.02 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.29 | $0.91 |
| 52 Week High | $8.28 | $1.92 |
| Indicator | SLNG | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 39.08 | 49.05 |
| Support Level | $4.92 | $1.35 |
| Resistance Level | $5.17 | $1.49 |
| Average True Range (ATR) | 0.15 | 0.08 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 6.06 | 31.82 |
Stabilis Solutions Inc is an energy transition company that provides turnkey clean energy production, storage, transportation, and fueling solutions using liquefied natural gas (LNG) to multiple end markets. The company provides LNG solutions to customers in diverse end markets, including aerospace, agriculture, energy, industrials, marine bunkering, mining, pipeline, remote power, and utility markets. It generates revenue by selling and delivering LNG to its customers, renting cryogenic equipment, and providing engineering and field support services. It has a geographical presence in the United States and Mexico.
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.